Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes

Dongmei Han, Carlos A. Leyva, Della Matheson, Davide Mineo, Shari Messinger, Bonnie B. Blomberg, Ana Hernandez, Luigi F. Meneghini, Gloria Allende, Jay S. Skyler, Rodolfo Alejandro, Alberto Pugliese, Norma S. Kenyon

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

There is a need for biomarkers to monitor the development and progression of type 1 DM. We analyzed mRNA expression levels for granzyme B, perforin, fas ligand, TNF-αalpha;, IFN-γgamma;, Foxp3, IL-10, TGF-βbeta;, IL-4, IL-6, IL-17, Activation-induced cytidine deaminase (AID) and Immunoglobulin G gamma chain (IgG<gamma>) genes in peripheral blood of at-risk, new-onset and long-term type 1 DM , and healthy controls. The majority of the genes were suppressed in long-term type 1 DM compared to controls and new-onset patients. IFN-γ, IL-4 and IL-10 mRNA levels were significantly higher in new-onset compared to at-risk and long-term groups. There was decreased mRNA expression for AID and IgG<gamma> and up-regulation of IFN-γ with age in controls. Data suggest an overall depressed immunity in long-term type 1 DM. Increased gene expression levels for IFN-γ, IL-4 and IL-10 in new-onset patients from at-risk patients might be used as potential markers for progression of the disease.

Original languageEnglish (US)
Pages (from-to)290-301
Number of pages12
JournalClinical Immunology
Volume139
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Immunoglobulin gamma-Chains
Gene Expression Profiling
Type 1 Diabetes Mellitus
Interleukin-4
Interleukin-10
Messenger RNA
Immunoglobulin G
Fas Ligand Protein
Interleukin-17
Transforming Growth Factor beta
Genes
Disease Progression
Immunity
Interleukin-6
Up-Regulation
Tumor Necrosis Factor-alpha
Biomarkers
Gene Expression
AICDA (activation-induced cytidine deaminase)

Keywords

  • Age
  • Biomarkers
  • Cytokines
  • Cytotoxic lymphocyte genes
  • Gene expression
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Han, D., Leyva, C. A., Matheson, D., Mineo, D., Messinger, S., Blomberg, B. B., ... Kenyon, N. S. (2011). Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clinical Immunology, 139(3), 290-301. https://doi.org/10.1016/j.clim.2011.02.016

Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. / Han, Dongmei; Leyva, Carlos A.; Matheson, Della; Mineo, Davide; Messinger, Shari; Blomberg, Bonnie B.; Hernandez, Ana; Meneghini, Luigi F.; Allende, Gloria; Skyler, Jay S.; Alejandro, Rodolfo; Pugliese, Alberto; Kenyon, Norma S.

In: Clinical Immunology, Vol. 139, No. 3, 06.2011, p. 290-301.

Research output: Contribution to journalArticle

Han, D, Leyva, CA, Matheson, D, Mineo, D, Messinger, S, Blomberg, BB, Hernandez, A, Meneghini, LF, Allende, G, Skyler, JS, Alejandro, R, Pugliese, A & Kenyon, NS 2011, 'Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes', Clinical Immunology, vol. 139, no. 3, pp. 290-301. https://doi.org/10.1016/j.clim.2011.02.016
Han, Dongmei ; Leyva, Carlos A. ; Matheson, Della ; Mineo, Davide ; Messinger, Shari ; Blomberg, Bonnie B. ; Hernandez, Ana ; Meneghini, Luigi F. ; Allende, Gloria ; Skyler, Jay S. ; Alejandro, Rodolfo ; Pugliese, Alberto ; Kenyon, Norma S. / Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. In: Clinical Immunology. 2011 ; Vol. 139, No. 3. pp. 290-301.
@article{d5633e7f3f084fc6af9a2fb1fbeac778,
title = "Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes",
abstract = "There is a need for biomarkers to monitor the development and progression of type 1 DM. We analyzed mRNA expression levels for granzyme B, perforin, fas ligand, TNF-αalpha;, IFN-γgamma;, Foxp3, IL-10, TGF-βbeta;, IL-4, IL-6, IL-17, Activation-induced cytidine deaminase (AID) and Immunoglobulin G gamma chain (IgG) genes in peripheral blood of at-risk, new-onset and long-term type 1 DM , and healthy controls. The majority of the genes were suppressed in long-term type 1 DM compared to controls and new-onset patients. IFN-γ, IL-4 and IL-10 mRNA levels were significantly higher in new-onset compared to at-risk and long-term groups. There was decreased mRNA expression for AID and IgG and up-regulation of IFN-γ with age in controls. Data suggest an overall depressed immunity in long-term type 1 DM. Increased gene expression levels for IFN-γ, IL-4 and IL-10 in new-onset patients from at-risk patients might be used as potential markers for progression of the disease.",
keywords = "Age, Biomarkers, Cytokines, Cytotoxic lymphocyte genes, Gene expression, Type 1 diabetes",
author = "Dongmei Han and Leyva, {Carlos A.} and Della Matheson and Davide Mineo and Shari Messinger and Blomberg, {Bonnie B.} and Ana Hernandez and Meneghini, {Luigi F.} and Gloria Allende and Skyler, {Jay S.} and Rodolfo Alejandro and Alberto Pugliese and Kenyon, {Norma S.}",
year = "2011",
month = "6",
doi = "10.1016/j.clim.2011.02.016",
language = "English (US)",
volume = "139",
pages = "290--301",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes

AU - Han, Dongmei

AU - Leyva, Carlos A.

AU - Matheson, Della

AU - Mineo, Davide

AU - Messinger, Shari

AU - Blomberg, Bonnie B.

AU - Hernandez, Ana

AU - Meneghini, Luigi F.

AU - Allende, Gloria

AU - Skyler, Jay S.

AU - Alejandro, Rodolfo

AU - Pugliese, Alberto

AU - Kenyon, Norma S.

PY - 2011/6

Y1 - 2011/6

N2 - There is a need for biomarkers to monitor the development and progression of type 1 DM. We analyzed mRNA expression levels for granzyme B, perforin, fas ligand, TNF-αalpha;, IFN-γgamma;, Foxp3, IL-10, TGF-βbeta;, IL-4, IL-6, IL-17, Activation-induced cytidine deaminase (AID) and Immunoglobulin G gamma chain (IgG) genes in peripheral blood of at-risk, new-onset and long-term type 1 DM , and healthy controls. The majority of the genes were suppressed in long-term type 1 DM compared to controls and new-onset patients. IFN-γ, IL-4 and IL-10 mRNA levels were significantly higher in new-onset compared to at-risk and long-term groups. There was decreased mRNA expression for AID and IgG and up-regulation of IFN-γ with age in controls. Data suggest an overall depressed immunity in long-term type 1 DM. Increased gene expression levels for IFN-γ, IL-4 and IL-10 in new-onset patients from at-risk patients might be used as potential markers for progression of the disease.

AB - There is a need for biomarkers to monitor the development and progression of type 1 DM. We analyzed mRNA expression levels for granzyme B, perforin, fas ligand, TNF-αalpha;, IFN-γgamma;, Foxp3, IL-10, TGF-βbeta;, IL-4, IL-6, IL-17, Activation-induced cytidine deaminase (AID) and Immunoglobulin G gamma chain (IgG) genes in peripheral blood of at-risk, new-onset and long-term type 1 DM , and healthy controls. The majority of the genes were suppressed in long-term type 1 DM compared to controls and new-onset patients. IFN-γ, IL-4 and IL-10 mRNA levels were significantly higher in new-onset compared to at-risk and long-term groups. There was decreased mRNA expression for AID and IgG and up-regulation of IFN-γ with age in controls. Data suggest an overall depressed immunity in long-term type 1 DM. Increased gene expression levels for IFN-γ, IL-4 and IL-10 in new-onset patients from at-risk patients might be used as potential markers for progression of the disease.

KW - Age

KW - Biomarkers

KW - Cytokines

KW - Cytotoxic lymphocyte genes

KW - Gene expression

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79955965390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955965390&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2011.02.016

DO - 10.1016/j.clim.2011.02.016

M3 - Article

C2 - 21414848

AN - SCOPUS:79955965390

VL - 139

SP - 290

EP - 301

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -